Solid progress in development of
Second quarter, 1 August -
- Net sales amounted to
SEK 2,890k (3,022k). - Operating result (EBIT) amounted to
SEK -3,409k (-4,221k). - Net result for the period amounted to
SEK -3,256k (-4,149k). - Earnings per share amounted to
SEK -0.81 (-1.03). Earnings per share after dilution amounted toSEK -0.81 (-1.03). - Cash flow from operating activities amounted to
SEK -4,143k (-1,835k). - Net cash flow amounted to
SEK -11,560k (-5,854k). - Prioritization and optimization, and the fact that development costs culminate this fiscal year (23/24), will facilitate significantly lower costs next fiscal year (24/25).
First half year, 1 May -
- Net sales increased to
SEK 6,317k (5,785k). - Operating result (EBIT) amounted to
SEK -8,821k (-9,093k). - Net result for the period amounted to
SEK -8,255k (-8,980k). - Earnings per share amounted to -2.05
(-2.23) SEK . Earnings per share after dilution amounted to -2.05(-2.23) SEK . - Cash flow from operating activities amounted to
SEK -10,013k (-5,682k). - Net cash flow amounted to
SEK -23,930k (-12,791k).
During the quarter, we had stable sales in the data analysis area. Within the cancer diagnostics area, which we address with the products
The work to prepare
CE marking according to the IVDR regulations for medical devices is a requirement for use in diagnostics in healthcare. Estimated time of regulatory approval (CE marking) for childhood acute lymphoblastic leukemia (BCP-ALL) is
The work on the first generation of
At the end of October, the
We have great confidence in our strategy. To conserve existing resources and compensate for the time delay previously communicated, we will focus on the four cancer types where we have progressed the most. These consist of childhood and adult leukemia, bladder cancer, and lung cancer.
As we approach a new phase in the development of
Net sales in the second quarter amounted to
Cancer diagnosis
Together with partners, we continue to develop and refine diagnostic tests (models) for lung cancer, bladder cancer and adult acute myeloid leukemia (AML). Models for childhood acute lymphoblastic leukemia (BCP-ALL) and the three other areas are available for use in the Qlucore Insights product. Qlucore Insights is licensed to customers for research use, and Qlucore Insights model for acute lymphoblastic leukemia has already been sold to several customers.
Global landscape
Global uncertainty with the deteriorating geopolitical situation combined with economic trends, such as rising inflation and the risk of recession, has not affected operations during the period, as far as we can judge. Furthermore, we have noted a growing trend for redundancies in the technology sector, in areas such as biotech, especially in the
In
I can happily state that our development work is going well, that we have moved to more appropriate premises and that I look to the future with great confidence.
CEO
[1] EU regulation 2017/746 on in vitro diagnostic medical devices (IVDR).
© Modular Finance, source